Abiraterone Access expanded for High-Risk Prostate Cancer Patients in England
Thousands of men in England diagnosed with high-risk, non-metastatic prostate cancer will now have access to the drug abiraterone, following a recent decision by NHS England. This expanded access aims to improve outcomes for patients whose cancer is at a higher risk of spreading, even if it hasn’t yet.
Previously, abiraterone was primarily reserved for patients with prostate cancer that had already spread. Tho, clinical trial evidence has demonstrated significant benefits when used earlier in the disease course for those with high-risk characteristics. The decision follows a positive proposal from the National Institute for Health and Care Excellence (NICE) and is expected to benefit approximately 1,600 men annually. NICE Final Guidance
What is Abiraterone?
Abiraterone acetate is a type of hormone therapy. Prostate cancer ofen relies on male hormones (androgens) to grow. Abiraterone works by reducing the amount of androgens the body produces, slowing or stopping the growth of cancer cells. It is indeed administered as a daily tablet and is typically used in combination with a steroid, such as prednisone, to manage side effects. Cancer Research UK – Abiraterone
Who Will Benefit from This Change?
The expanded access applies to men newly diagnosed with high-risk, non-metastatic prostate cancer. High-risk factors typically include a high Gleason score (a measure of how aggressive the cancer cells look under a microscope) or a high level of prostate-specific antigen (PSA). The exact criteria for eligibility will be steadfast by individual clinicians, but the aim is to identify patients who are most likely to benefit from early intervention with abiraterone.
Clinical Trial Evidence
the decision to expand access to abiraterone is based on robust evidence from clinical trials, most notably the STAMPEDE trial. This trial showed that adding abiraterone to standard hormone therapy substantially improved overall survival and reduced the risk of cancer progression in men with high-risk, non-metastatic prostate cancer. STAMPEDE Trial
What Does This Mean for Patients?
This approval offers a significant advancement in the treatment of high-risk prostate cancer. By starting abiraterone earlier, doctors hope to delay or prevent the cancer from spreading, potentially improving long-term survival rates and quality of life for affected men. Patients should discuss their individual circumstances and treatment options with their oncologist to determine if abiraterone is appropriate for them.
Key Takeaways
- NHS England has approved wider access to abiraterone for men with high-risk, non-metastatic prostate cancer.
- Abiraterone is a hormone therapy that reduces androgen levels, slowing cancer growth.
- Clinical trials, such as STAMPEDE, have demonstrated significant benefits of early abiraterone treatment.
- Approximately 1,600 men per year are expected to benefit from this change.
- Patients should discuss treatment options with their oncologist.
